Top

High Blood Pressure & Cardiovascular Prevention

Published in:

01-01-2008 | Original Research Article

Elevated B-Type Natriuretic Peptide Blood Levels during Hypertensive Crisis

A Novel Diagnostic Marker of Acute Coronary and Cerebrovascular Events?

Authors: Prof. Salvatore Di Somma, Alberto Sentimentale, Laura Magrini, Federica Tega, Rossella Marino, Enric Ferri, Federica Fioretti, Arianna Trabalzini, Giuliano Bertazzoni

Published in: High Blood Pressure & Cardiovascular Prevention | Issue 1/2008

Abstract

Objectives: The objectives of this study were: (i) to assess the role of B-type natriuretic peptide (BNP) in the course of hypertensive crisis; (ii) to evaluate the possible role of BNP in the differential diagnosis between hypertensive emergencies (HE) or urgencies (HU); and (iii) to investigate the relationship between BNP concentration and blood pressure (BP) acute burden with consequent myocardial ischaemia or brain damage.

Methods: 57 consecutive patients were admitted to the emergency department for acute elevated BP levels (systolic BP [SBP]/diastolic BP [DBP]: 200.7 ± 24.7/121.2 ± 12.4 mmHg) were enrolled. On the basis of clinical data, patients were subdivided into two groups: (i) 25 patients with HE: SBP/DBP 204.16 ± 29.1/123.3 ± 13.0 mmHg with heart (acute coronary syndrome) or brain involvement; (ii) 32 patients with HU: SBP/DBP 198.1 ± 20.7/120 ± 11.7 mmHg, without any acute or ongoing deterioration of target organs. For each patient, a serum dosage of BNP was performed.

Results: In the whole population, no significant relationship was found between BP total burden and BNP level. In HE, BNP concentration (113.22 ± 87 pg/mL) was significantly (p < 0.001) higher than in HU (23.5 ± 21.3 pg/mL) patients. There was a significant increase (p < 0.01) of BNP blood level in HE patients with acute coronary syndrome (162.02 ± 95.7 pg/mL) compared with those with neurological complications (80.7 ± 65.2 pg/mL). Moreover, in HU patients, there was a significant relationship (r = 0.37; p < 0.05) between BNP levels and pulse pressure.

Conclusions: During hypertensive crisis, BNP blood level increase seems to have a role as a diagnostic tool for the screening of hypertensive emergencies due to an acute coronary or brain injury, and the BNP elevation is greater in the presence of myocardial ischaemia than brain damage.

The use of trade names is for product identification purposes only and does not imply endorsement.

Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National high blood pressure educational program coordinating committee. Hypertension 2003; 42: 1206–52PubMedCrossRef

Gegenhuber A, Lenz K. Hypertensive emergency and urgency. Herz. 2003; 28(8): 717–24PubMedCrossRef

Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest 2000; 118: 214–27PubMedCrossRef

Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for management of hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87PubMedCrossRef

Vidt DG. Emergency room management of hypertensive urgencies and emergencies. J Clin Hypertens (Greenwich) 2001; 3(3): 158–64CrossRef

Martin JF, Higashiama E, Garcia E, et al. Hypertensive crisis profile: prevalence and clinical presentation. Arq Bras Cardiol 2004; 83(2): 131–6PubMedCrossRef

Zampaglione B, Pascale C, Marchisio M, et al. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension 1996; 27: 144–7PubMedCrossRef

Kaplan NM. Hypertensive crises. In: Kaplan NM, editor. Clinical hypertension. 6th ed. Baltimore (MD): Williams & Wilkins, 1994: 281–97

Aggarwal M, Khan IA. Hypertensive crisis: hypertensive emergencies and urgencies. Cardiol Clin 2006; 24(1): 135–46PubMedCrossRef

10.

Varon J, Marik PE. Clinical review: the management of hypertensive crisis. Crit Care 2003; 7(5): 374–84PubMedCrossRef

11.

Magga J, Vuolteenaho O, Tokola H, et al. B-type natriuretic peptide: a myocitespecific marker for characterizing load-induced alteration in cardiac gene expression. Ann Med 1998; 30Suppl. 1: 39–45PubMed

12.

De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014–21PubMedCrossRef

13.

Silver MA. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic screening, treatment monitoring and therapeutic roles of natriuretic peptides in cardiovascular disease. Heart Fail 2004; 8Suppl. 3: S3–S14

14.

Di somma S, Magrini K, Mazzone M, et al. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. Am J Em Med 2007; 25: 335–9CrossRef

15.

Tihtonen KM, Koobi T, Vuolteenaho O, et al. Natriuretic peptides and hemodynamics in preeclampsia. Am J Obstet Gynecol 2007; 196(1): 328.e.1–7

16.

Nakagawa K, Yamaguchi T, Seida M, et al. Plasma concentrations of atrial and brain natriuretic peptides in a case with hypertensive encephalopathy. Neurol Res 2002; 24(6): 627–30PubMedCrossRef

17.

Rickham PP. Human experimentation: code of ethics of the world medical association–Declaration of Helsinki. BMJ 1964; 2(5402): 177

18.

Stroke Prevention and Educational Awareness Diffusion. Italian guidelines for prevention and treatment [in Italian]. 4th ed. Milan: Publications Catel, 2005

19.

Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 671–719PubMedCrossRef

20.

Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary. J Am Coll Cardiol 2007; 50: 652–726CrossRef

21.

Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cadiol 2002; 39: 202–9CrossRef

22.

Maisel AS, Krishnaswamy P, Richard M, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347(3): 161–7PubMedCrossRef

23.

Body R, Roberts C. Brain natriuretic peptide as a potential marker of acute coronary syndromes. Emerg Med J 2006; 23: 403–7PubMedCrossRef

24.

Bassan R, Patsch A, Maisel A, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no STsegment elevation. Eur Heart J 2005; 26: 234–40PubMedCrossRef

25.

Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Eng J Med 1998; 339(5): 321–8CrossRef

26.

Borghi C, Esposti D, Immordino V, et al. Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclamosia. Am J Obstet Gynecol 2000; 183: 140–7PubMed

27.

Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254–8PubMedCrossRef

28.

Kohno M, Horio T, Yokokaw K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29–34PubMedCrossRef

29.

Naruse M, Takeyama Y, Taanab A, et al. Atrial and brain natriuretic peptides in cardiovascular disease. Hypertension 1994; 23Suppl. I: 231–4CrossRef

30.

Suzuki M, Hamada M, Yamamoto K. Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25(5): 669–76PubMedCrossRef

31.

James SK, Lindahl B, Siegbahn M. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary heart disease: a Global Utilization of strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275–81PubMedCrossRef

32.

Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005; 294(22): 2866–71PubMedCrossRef

33.

De Lemos JA, Morrow DA. Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes. Am Heart J 2007; 153(4): 450–3PubMedCrossRef

34.

Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in expression in experimental acute myocardial infarction. Circulation 1995; 92: 1558–64PubMedCrossRef

35.

Staub D, Nusbaumer C, Zellweger M, et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J 2006; 151: 1223–30PubMedCrossRef

36.

Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44(10): 1988–95PubMedCrossRef

37.

Windhausen F, Hirsch A, Sanders GT, et al. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J 2007; 153(4): 485–92CrossRef

38.

Fukui S, Katoh H, Tsuzuki N, et al. Focal brain edema and natriuretic peptides in patients with subarachnoid hemorrage. J Clin Neurosci 2004; 11(5): 507–11PubMedCrossRef

39.

Sviri GE, Shik V, Raz B, et al. Role of brain natriuretic peptide in cerebral vasospasm. Acta Neurochir 2003; 145: 851–60CrossRef

40.

Nakagawa K, Yamaguchi T, Seida M, et al. plasma concentration of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis 2005; 19: 157–64PubMedCrossRef

41.

Iltumour K, Karabulut A, Apak I, et al. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J 2006; 151: 1115–22CrossRef

42.

Tomida M, Muraki M, Uemura K, et al. Plasma concentrations of brain natriuretic peptide in patients with subar-achnoid hemorrhage. Stroke 1998; 29: 158–1587CrossRef

43.

Franzoni MF, Canonaco M, Frova A, et al. Brain natriuretic peptide (BNP) likeimmunoreactivity in the central nervous system of the crested newt. Eur J Histochem 1992; 36: 455–66PubMed

44.

Di Angelantonio E, De Castro S, Toni D, et al. Determinants of plasma levels of brain natriuretic peptide after acute ischemic stroke or TIA. J Neurol Sci 2007; 260(1-2): 139–42PubMedCrossRef

Title: Elevated B-Type Natriuretic Peptide Blood Levels during Hypertensive Crisis
A Novel Diagnostic Marker of Acute Coronary and Cerebrovascular Events?
Authors: Prof. Salvatore Di Somma
Alberto Sentimentale
Laura Magrini
Federica Tega
Rossella Marino
Enric Ferri
Federica Fioretti
Arianna Trabalzini
Giuliano Bertazzoni
Publication date: 01-01-2008
Publisher: Springer International Publishing
Published in: High Blood Pressure & Cardiovascular Prevention / Issue 1/2008
Print ISSN: 1120-9879
Electronic ISSN: 1179-1985
DOI: https://doi.org/10.2165/00151642-200815010-00005

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Elevated B-Type Natriuretic Peptide Blood Levels during Hypertensive Crisis

A Novel Diagnostic Marker of Acute Coronary and Cerebrovascular Events?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Industry Pulse

The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension

Is New-Onset Diabetes Mellitus Important?

The Association of Tobacco Smoking and Blood Pressure in Some Low Socioeconomic Groups from Andhra Pradesh, India

Cardiovascular Risk Management in Clinical Practice

Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page